Physician profile

Andrew Demaio

Pulmonary Disease · Baltimore, MD

NPI 1487072153

$1,486.33

in general payments reported to CMS, 2019-2025

7 companies · $434 in 2025

The $434 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

See the full distribution for Pulmonary Disease

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$847.72

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Erbe USA INC $615.91 2021-2025 Vio/Cryo/Apc, Vio3 Cryo Apc
Astrazeneca Pharmaceuticals LP $247.46 2025
Boston Scientific Corporation $200.27 2023
Intuitive Surgical, INC. $174.76 2021-2023 Da Vinci Surgical System
Ethicon INC. $147.64 2021-2022
Medtronic, INC. $100.29 2024 Illumisite

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Andrew Demaio

$1,486.33

in general payments reported 2019-2025

Years
2021-2025
Top company
Erbe USA INC
Context
The $434 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/7366840/andrew-demaio

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.